1. Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, […]readmore
Tags : Catalent
Shots: Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Italy and prepare for large-scale commercial supply of AZD1222 The agreement ramps up […]readmore
Shots: The alliance includes joint investment and tech transfer to accelerate rapid scale-up of segregated manufacturing capacity over the coming months for supporting J&J’s vaccine candidates Catalent will accelerate the […]readmore
The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days […]readmore
Shots: Catalent to purchase BMS’ oral solid, biologics, and sterile product manufacturing and packaging facility and will continue to manufacture BMS’s current product portfolio at the site, providing facilities in […]readmore